Podcast

0.50 CME/CE Credit

Breaking the Opioid Cycle: A Practical Training Program for Tapering Opioids in Primary Care

Tapering opioids is frequently necessary in clinical practice, either to reduce harm or because of lack of significant benefit. The most important aspect of opioid tapering is discussing the reasons for it with the patient. Opioid tapering should be a measure of safety—and in no way punitive. Complete this activity to learn appropriate and inappropriate reasons for tapering opioid therapy and strategies to counsel patients and manage withdrawal and psychological issues.

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.

Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf
for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).

References:
1. CDC Clinical Practice Guideline for Prescribing Opioids for Pain – United States, 2022. MMWR 2022;71:3
2. Covington EC, Argoff CE, Ballantyne JC, et al. Ensuring Patient Protections When Tapering Opioids: Consensus Panel Recommendations. Mayo Clinic Proc 202 Oct;95(10):2155-2171.
3. da Costa BR et al. Cochrane Database Syst Rev. 2014;(9):CD003115; Krebs EE et al. JAMA. 2018;319(9):872-882; Abdel Shaheed C et al. JAMA Intern Med. 2016;176(7):958-968.
4. Darnall BD, Colloca L. Int Rev Neurobiol. 2018;139:129–157.
5. HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opioid Analgesics. Accessed September 23, 2024. https://www.cms.gov/about-cms/story-page/cdcs-tapering-guidance.pdf
6. Passik SD, Weinreb HJ. Adv Ther. 2000;17(2):70-83.

Begin

Already listened on another platform?

CME/CE Information

0.50 AMA PRA Category 1 Credits™, 0.50 ABIM MOC or 0.40 AANP, including 0.20 AANP Pharm

Release Date: 10/16/2023

Expiration Date: 10/31/2025

Topics

Faculty

Charles E. Argoff, MD, FABPM

Learning Objectives

Identify strategies for ongoing safe and effective use of opioids in patients with chronic pain, including titration, referral, and discontinuation, when appropriate
Summarize counseling strategies for caregivers and patients on opioid therapy

State Licensure Requirements

This activity satisfies topic-specific CME/CE requirements (pain management, controlled substances, etc.) of many state licensing boards. Please check with your state’s licensing boards for specific requirements, and print this page as appropriate for documentation.

Iowa: This activity is designed to satisfy requirements of ARNPs, for CE regarding the US Centers for Disease Control and Prevention Guideline for prescribing opioids for chronic pain. Please print this page as documentation, for submission with your CE certificate.

Texas: This activity is approved for Pain Management and Prescription of Opioids requirements from the Texas Medical Board/Board of Nursing, as well as Medical Ethics and/or Professional Responsibility.

This activity satisfies training requirements for the MATE Act, which requires all DEA-registered practitioners to complete 8 hours of CME/CE credit on opioid or other substance use disorders. Please visit https://www.pri-med.com/state/mate-act-cme for more information about the MATE Act.

Looking for more mental health CME?

Enroll in Mental Health Bootcamp, an on-demand curriculum with over 30 courses, a library of downloadable resources, and Q&A with faculty.

Learn More

Faculty

Charles E. Argoff, MD, FABPM

Vice Chair
Professor of Neurology and Urology
Albany Medical College
Director, Comprehensive Pain Center
Director, Pain Management Fellowship
Albany Medical Center
Albany, New York

Learn More

Disclosures

The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.

Charles E. Argoff, MD, FABPM: Speaker’s bureau: AbbVie, Amgen, Averitas Pharma, Biohaven, Grunenthal, Impel Pharmaceuticals, Kowa Pharmaceuticals America, Lilly, Lundbeck, Nevro, and Teva.
Advisory Board: AbbVie, Amgen, Averitas Pharma, Clexio Biosciences, EnZen Therapeutics, Kowa, Lundbeck, Nevro, Tremeau Pharmaceuticals, Tris Pharma, Vertex and Xgene Pharma.
Consultant: Neumentum, PainScripts, and Tris Pharma.
Researcher: AbbVie, Amgen, Lilly, Lundbeck, and Teva.
Stock Holder: Pfizer and Trevena.

Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.

CME/CE Information

AMA PRA Category 1 Credits™

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners^® (AANP) through the joint providership of Pri-Med Institute and Miller Medical Communications Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.

Designation Statement

This activity is approved for 0.40 contact hour of continuing education, which includes 0.20 hour of pharmacology.

MOC Credit Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 2 out of the 2 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen. For PAs, the NCCPA accepts for Category 1 CME credit activities designated for AMA PRA Category 1 Credit.

Supported by

Opioid Analgesic REMS Program Companies

Education Partner

Miller Medical Communications, LLC

Fine Print

Computer System Requirements

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

Disclaimer

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Statement of Independence

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Disclosure Policies and Contacting Pri-Med Institute

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.